Ligand-induced conformational changes allosterically activate Toll-like receptor 9

被引:360
作者
Latz, Eicke [1 ]
Verma, Anjali
Visintin, Alberto
Gong, Mei
Sirois, Cherilyn M.
Klein, Dionne C. G.
Monks, Brian G.
McKnight, C. James
Lamphier, Marc S.
Duprex, W. Paul
Espevik, Terje
Golenbock, Douglas T.
机构
[1] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA
[2] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7489 Trondheim, Norway
[3] Norwegian Univ Sci & Technol, Dept Phys, N-7489 Trondheim, Norway
[4] Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA
[5] Queens Univ Belfast, Sch Biomed Sci, Ctr Canc Res & Cell Biol, Belfast BT7 9BL, Antrim, North Ireland
[6] Eisai Res Inst, Andover, MA 01810 USA
关键词
D O I
10.1038/ni1479
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Microbial and synthetic DNA rich in CpG dinucleotides stimulates Toll-like receptor 9 (TLR9), whereas DNA lacking CpG either is inert or can inhibit TLR9 activation. The molecular mechanisms by which TLR9 becomes activated or is inhibited are not well understood. Here we show that TLR9 bound to stimulatory and inhibitory DNA; however, only stimulatory DNA led to substantial conformational changes in the TLR9 ectodomain. In the steady state, 'inactive' TLR9 homodimers formed in an inactivated conformation. Binding of DNA containing CpG, but not of DNA lacking CpG, to TLR9 dimers resulted in allosteric changes in the TLR9 cytoplasmic signaling domains. In endosomes, conformational changes induced by DNA containing CpG resulted in close apposition of the cytoplasmic signaling domains, a change that is probably required for the recruitment of signaling adaptor molecules. Our results indicate that the formation of TLR9 dimers is not sufficient for its activation but instead that TLR9 activation is regulated by conformational changes induced by DNA containing CpG.
引用
收藏
页码:772 / 779
页数:8
相关论文
共 48 条
[1]   Medicinal chemistry and therapeutic potential of CpG DNA [J].
Agrawal, S ;
Kandimalla, ER .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (03) :114-121
[2]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[3]  
2-U
[4]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[5]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[6]   Sequence requirements for oligodeoxyribonucleotide inhibitory activity [J].
Ashman, RF ;
Goeken, JA ;
Drahos, J ;
Lenert, P .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (04) :411-420
[7]   Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus [J].
Barrat, FJ ;
Meeker, T ;
Gregorio, J ;
Chan, JH ;
Uematsu, S ;
Akira, S ;
Chang, B ;
Duramad, O ;
Coffman, RL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (08) :1131-1139
[8]   The dsRNA binding site of human toll-like receptor 3 [J].
Bell, Jessica K. ;
Askins, Janine ;
Hall, Pamela R. ;
Davies, David R. ;
Segal, David M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (23) :8792-8797
[9]   Leucine-rich repeats and pathogen recognition in Toll-like receptors [J].
Bell, JK ;
Mullen, GED ;
Leifer, CA ;
Mazzoni, A ;
Davies, DR ;
Segal, DM .
TRENDS IN IMMUNOLOGY, 2003, 24 (10) :528-533
[10]   The molecular structure of the Toll-like receptor 3 ligand-binding domain [J].
Bell, JK ;
Botos, I ;
Hall, PR ;
Askins, J ;
Shiloach, J ;
Segal, DM ;
Davies, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :10976-10980